MDT-AP-1258
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 108
- os_event
- false
- age_years
- 10
- sex
- M
- new_clusters
- C6
- umap1_2d
- 4.053108925
- umap2_2d
- 5.92241445
- umap1_3d
- 2.536478285
- umap2_3d
- -1.733162139
- umap3_3d
- -4.120722283
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.440
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.360
- MITOTIC_SPINDLE+0.330
- HEME_METABOLISM+0.200
- PEROXISOME+0.170
- FATTY_ACID_METABOLISM+0.160
- PROTEIN_SECRETION+0.130
- MYC_TARGETS_V1+0.100
- OXIDATIVE_PHOSPHORYLATION+0.100
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- KRAS_SIGNALING_UP-0.460
- TNFA_SIGNALING_VIA_NFKB-0.440
- ALLOGRAFT_REJECTION-0.430
- IL6_JAK_STAT3_SIGNALING-0.410
- NOTCH_SIGNALING-0.390
- ANGIOGENESIS-0.350
- COAGULATION-0.350
- INTERFERON_GAMMA_RESPONSE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1366 | Med | Medulloblastoma | 0.946 |
| 2 | MDT-AP-0357 | Med | Medulloblastoma | 0.920 |
| 3 | MDT-AP-0113 | Med | Medulloblastoma | 0.917 |
| 4 | MDT-AP-0553 | Med | Medulloblastoma | 0.912 |
| 5 | SRR23303743 | — | — | 0.909 |
| 6 | MDT-AP-2917 | Med | Medulloblastoma | 0.906 |
| 7 | MDT-AP-0382 | Med | Medulloblastoma | 0.902 |
| 8 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.892 |
| 9 | BS_NKEAAFMW | medulloblastoma | — | 0.890 |
| 10 | BS_BSV07M7Z | medulloblastoma | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.440 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |